Egetis establishes subsidiary in the United States
August 10, 2022
Stockholm, Sweden, August 10, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that it has established a wholly-owned subsidiary in the United States, Egetis Therapeutics US Inc., incorporated in the state of Delaware.
The United States is a key market for patients suffering from MCT8 deficiency. Through the establishment of Egetis Therapeutics US Inc. the Company will continue the stepwise build-up of a commercial infrastructure in the US for the launch of Egetis lead drug candidate Emcitate. In the US, the Company is on track to submit an NDA for Emcitate in mid-2023 under the Fast-Track Designation granted by the FDA, after conducting a small randomized, placebo-controlled study in 16 patients to verify the results on thyroid hormone T3 levels seen in previous clinical trials and publications.
As previously announced, Sara Melton was appointed as President of North America at Egetis.
Nicklas Westerholm, CEO and President, Egetis Therapeutics AB, commented: “I am delighted we have managed to establish a US subsidiary in a very short time frame. We are looking forward to building a small and effective team to allow us to bring Emcitate, after approval, to the MCT8-deficiency patients who urgently need new treatment options.”